SCYX 7158

SCYX-7158 (AN-5568) is an antiprotozoal drug invented by Anacor Pharmaceuticals in 2009, and now under development by the Drugs for Neglected Diseases Initiative for the treatment of African trypanosomiasis (Sleeping sickness). It is a structurally novel drug described as a benzoxaborole derivative, and is the first orally active drug treatment developed for sleeping sickness. Phase I human clinical trials were completed successfully in 2015, and it is now in Phase IIb/III trials being carried out in the Democratic Republic of the Congo, where most cases of sleeping sickness occur.